Glenmark has received approval for Sirolimus tablets, 0.5mg, 1mg, and 2mg

After the announcement of Pulmonary Fibrosis treatment in India Glenmark has announced today about receiving approval for Sirolimus tablets, 0.5mg, 1mg, and 2mg.In a regulatory filing, Glenmark said ” Glenmark Pharmaceuticals Inc., USA (Glenmark) has received
final approval by the United States Food & Drug Administration (U.S. FDA) for Sirolimus Tablets, 0.5 mg, 1 mg and 2 mg, the generic version of Rapamune®1 Tablets, 0.5 mg, 1 mg, and 2 mg, of PF Prism CV.”